These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28245951)

  • 1. Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium.
    van Kampen RJW; Ramaekers BLT; Lobbezoo DJA; de Boer M; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FPJ; van Riel JMG; Peters NAJB; Tjan-Heijnen VCG; Joore MA
    Eur J Cancer; 2017 Jul; 79():238-246. PubMed ID: 28245951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer.
    Wu Q; Wang X; Zhang M; Liao W; Wang F; Li Q
    Oncol Res Treat; 2020; 43(4):153-159. PubMed ID: 32187596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
    Rodgers M; Soares M; Epstein D; Yang H; Fox D; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():1-12. PubMed ID: 21609648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France.
    Petitjean A; Smith-Palmer J; Valentine W; Tehard B; Roze S
    BMC Cancer; 2019 Feb; 19(1):140. PubMed ID: 30744578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
    Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
    JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
    Montero AJ; Avancha K; Glück S; Lopes G
    Breast Cancer Res Treat; 2012 Apr; 132(2):747-51. PubMed ID: 22200867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Markov model and cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer.
    Refaat T; Choi M; Gaber G; Kiel K; Mehta M; Gradishar W; Small W
    Am J Clin Oncol; 2014 Oct; 37(5):480-5. PubMed ID: 23388565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation.
    Dedes KJ; Matter-Walstra K; Schwenkglenks M; Pestalozzi BC; Fink D; Brauchli P; Szucs TD
    Eur J Cancer; 2009 May; 45(8):1397-406. PubMed ID: 19147344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
    Candon D; Healy J; Crown J
    Acta Oncol; 2014 Feb; 53(2):201-8. PubMed ID: 24125103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of continuing bevacizumab plus chemotherapy versus chemotherapy alone after first progression of metastatic colorectal cancer.
    Li Y; Hu M; Zhang Z; Chu M; Xu R; Liu L; Dong W; Yang M; Zhang R
    Cancer Med; 2024 Jan; 13(1):e6904. PubMed ID: 38186268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer.
    Leung HWC; Chan ALF; Muo CH; Leung JH
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):207-213. PubMed ID: 28965422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.
    Benedict A; Cameron DA; Corson H; Jones SE
    Pharmacoeconomics; 2009; 27(10):847-59. PubMed ID: 19803539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line bevacizumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimisation analysis.
    Nerich V; Bazan F; Compagnat F; Dobi E; Villanueva C; Chaigneau L; Perrin S; Voidey A; Pivot X; Limat S
    Anticancer Res; 2012 Aug; 32(8):3547-52. PubMed ID: 22843944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.
    Nerich V; Chelly J; Montcuquet P; Chaigneau L; Villanueva C; Fiteni F; Meneveau N; Perrin S; Voidey A; Monnot T; Pivot X; Limat S
    J Oncol Pharm Pract; 2014 Oct; 20(5):362-8. PubMed ID: 24158979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Durkee BY; Qian Y; Pollom EL; King MT; Dudley SA; Shaffer JL; Chang DT; Gibbs IC; Goldhaber-Fiebert JD; Horst KC
    J Clin Oncol; 2016 Mar; 34(9):902-9. PubMed ID: 26351332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens.
    Kikuchi Y; Uchida Y; Shirakawa K; Kanauchi H; Niwa T; Nishioka K; Tada K; Hashimoto M; Yasuda H; Sugiura R; Kawabata H; Seto Y; Ogawa T
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e231-e237. PubMed ID: 29498210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
    Wysham WZ; Schaffer EM; Coles T; Roque DR; Wheeler SB; Kim KH
    Gynecol Oncol; 2017 May; 145(2):340-345. PubMed ID: 28291545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women.
    Lairson DR; Parikh RC; Cormier JN; Chan W; Du XL
    Value Health; 2015 Dec; 18(8):1070-8. PubMed ID: 26686793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.
    Poonawalla IB; Parikh RC; Du XL; VonVille HM; Lairson DR
    Pharmacoeconomics; 2015 Nov; 33(11):1155-85. PubMed ID: 26072142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain.
    Frías C; Cortés J; Seguí MÁ; Oyagüez I; Casado MÁ
    Clin Transl Oncol; 2010 Oct; 12(10):692-700. PubMed ID: 20947484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.